Tenax Cleared to Start Clinical Testing of Oral Imatinib for PAH

Tenax Cleared to Start Clinical Testing of Oral Imatinib for PAH

308986

Tenax Cleared to Start Clinical Testing of Oral Imatinib for PAH

The U.S. Food and Drug Administration (FDA) has cleared Tenax Therapeutics to begin clinical testing of its new oral formulation of imatinib in people with pulmonary arterial hypertension (PAH). The company is planning to conduct a small pharmacological study this year — and then launch a Phase 3 clinical trial by June 2022 to test the therapy’s efficacy. “Tenax is thrilled we can now advance our imatinib PAH program towards pivotal testing,” Christopher Giordano, Tenax’s…

You must be logged in to read/download the full post.